| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Oct―28 |
Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a
SARS-CoV-2
Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2 |
Akira Kawano, Masamitsu N. Asaka, Mitsuo Kawano, Hidehisa Sekijima, Kae Sakai-Sugino, Hiroshi Komada, et al. (+6) Natsuko Yamakawa, Shigeo Horibata, Kazuhiro Matsuo, Myles O'Brien, Tetsuya Nosaka, Yasuhiro Yasutomi |
| 2 |
[GO] |
2025―Jan―20 |
Activation of Evolutionarily Young Endogenous Retroviruses Is Implicated in COVID-19 Immunopathology |
Reia Yoshida, Hitoshi Ohtani |
| 3 |
[GO] |
2023―Jul―11 |
The joy of the 11th International Fission Yeast Meeting in Hiroshima (POMBE2023 Hiroshima) after a long wait due to the COVID-19 pandemic |
Takashi Toda, Kenji Kitamura, Kazunori Kume, Masashi Yukawa, Takayuki Koyano, Masaru Ueno |
| 4 |
[GO] |
2022―Nov―19 |
Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model |
Satoru Morimoto, Koichi Saeki, Masaru Takeshita, Kunio Hirano, Mariko Shirakawa, Yumiko Yamada, et al. (+3) Shiho Nakamura, Fumiko Ozawa, Hideyuki Okano |
|
